Welcome to our dedicated page for Oric Pharmaceuticals SEC filings (Ticker: ORIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 200-page biotech disclosure isn’t easy—especially when ORIC Pharmaceuticals fills its 10-K with dense oncology data and detailed R&D spending tables. Investors hunting for cash runway, trial milestones or dilution risk often wade through scientific jargon that obscures what truly moves the stock.
Stock Titan solves this problem. Our AI-powered summaries turn every ORIC SEC filing into plain English, whether you need the ORIC quarterly earnings report 10-Q filing or an ORIC 8-K material events explained. Real-time alerts surface ORIC Form 4 insider transactions — real-time, so you can see when scientists or board members buy shares. Each document is linked to side-by-side metrics, making ORIC annual report 10-K simplified more than a slogan—it’s a three-minute read backed by machine learning.
- Track ORIC insider trading Form 4 transactions and spot patterns before catalysts.
- Compare R&D expense trends with revenue prospects using our ORIC earnings report filing analysis.
- Dive into options grants and severance terms inside the latest ORIC proxy statement executive compensation.
Whether you’re understanding ORIC SEC documents with AI for a diligence deep-dive or just need quick context on ORIC executive stock transactions Form 4, this page delivers every filing as it hits EDGAR—complete, searchable and explained simply. No more scrolling through appendices; the data that matters to oncology investors is already highlighted.
Oric Pharmaceuticals CFO Dominic Piscitelli executed significant stock sales on June 23-24, 2025, through a pre-planned Rule 10b5-1 trading plan established on December 30, 2024. The transactions included:
- June 23: Sale of 584 shares at $10.00 and 450 shares at $10.01
- June 24: Sale of 32,466 shares at weighted average price of $10.5045 (range $10.34-$10.80)
Following these transactions, Piscitelli's direct ownership decreased from 101,233 to 68,317 shares, representing a roughly 32.5% reduction in his holdings. The sales were executed according to a predetermined trading plan, which helps avoid concerns about insider trading by establishing sale parameters in advance. The transactions demonstrate significant insider selling activity by a key executive officer.
ORIC Pharmaceuticals has filed a 424B3 prospectus for the resale of up to 19,230,845 shares of common stock by selling stockholders. This includes 14,130,313 outstanding shares and 5,100,532 shares issuable upon exercise of pre-funded warrants from a May 2025 private placement that raised approximately $125 million at $6.50 per share.
The company is advancing two key clinical-stage candidates:
- ORIC-944: A PRC2 inhibitor for prostate cancer, showing promising Phase 1b results. Currently in combination trials with apalutamide and darolutamide. Phase 3 trial planned for H1 2026.
- ORIC-114: A brain-penetrant EGFR/HER2 inhibitor for solid tumors, demonstrating both systemic and intracranial activity. Phase 1b trials ongoing with data updates expected in H2 2025 and Phase 3 trials planned for 2026.
As an emerging growth company, ORIC focuses on developing therapies targeting cancer resistance mechanisms in hormone-dependent cancers, precision oncology, and tumor dependencies.
Insider Trading Alert: Angie You, Director at Oric Pharmaceuticals (ORIC), has made significant stock purchases over two consecutive days in June 2025:
- June 20, 2025: Acquired 26,597 shares at weighted average price of $9.3871 per share
- June 23, 2025: Purchased additional 1,403 shares at $9.43 per share
Total position following these transactions: 28,000 shares held directly. The first purchase was executed across multiple price points ranging from $9.14 to $9.50. These direct market purchases by a director signal potential confidence in the company's prospects. The transactions were reported via Form 4 filing and executed through an attorney-in-fact, Christian Kuhlen.
The SEC has declared Oric Pharmaceuticals' Form S-3 registration statement effective as of June 20, 2025, at 4:00 P.M. The registration statement was filed under file number 333-287949.
Form S-3 is a shelf registration that allows publicly traded companies to register securities for future public offerings. This effectiveness notice indicates that Oric Pharmaceuticals has met SEC requirements and can now proceed with their planned securities offering(s).
This regulatory development suggests that Oric Pharmaceuticals may be positioning itself for potential future capital raising activities, which could include offerings of common stock, preferred stock, debt securities, warrants, or other securities as specified in their registration statement.
FAQ
What is the current stock price of Oric Pharmaceuticals (ORIC)?
What is the market cap of Oric Pharmaceuticals (ORIC)?
What is the core focus of ORIC Pharmaceuticals?
Which therapeutic areas does ORIC emphasize?
How does ORIC generate revenue?
What differentiates ORIC from its competitors?
What is the significance of ORIC's pipeline?
How does ORIC incorporate modern technology into its R&D approach?
What are the primary categories of products being developed by ORIC?
How does ORIC's approach impact the overall treatment landscape in oncology?
